Quanterix Showcases Innovative Biomarker Technology at J.P. Morgan Healthcare Conference 2025

Quanterix Sets the Stage for Innovation at the J.P. Morgan Healthcare Conference

Quanterix Corporation, a pioneering entity in ultrasensitive biomarker detection, is poised to make a significant impact at the 43rd Annual J.P. Morgan Healthcare Conference, running from January 13 to 16, 2025. President and CEO Masoud Toloue is slated to present on January 15 at 4:30 p.m. PST, highlighting the company's advancements in medical diagnostics and research support. This conference is a pivotal gathering in the healthcare sector, where Quanterix will not only present but also engage in one-on-one meetings with institutional investors, fostering dialogue around its innovative technologies and future objectives.

At the heart of Quanterix's offerings is its proprietary Simoa® technology, which allows for the quantification of proteins at remarkably low levels, far surpassing traditional methods. This unparalleled sensitivity enables researchers to delve deeper into various medical fields, including neurology, oncology, immunology, cardiology, and infectious diseases. The company’s advanced digital immunoassay technology and its CLIA-certified Accelerator laboratory have been instrumental in driving scientific progress, contributing to over 3,100 publications in peer-reviewed journals over nearly two decades. These achievements underscore Quanterix's role as a key player in advancing healthcare research and improving disease management through innovative detection methods.

The J.P. Morgan Healthcare Conference provides an excellent platform for Quanterix to showcase its commitment to pushing the boundaries of biomarker detection and its contributions to scientific research. For those unable to attend, Quanterix offers a live webcast of the presentation through its website, along with a replay option for a limited time post-conference. The company’s forward-looking statements during the event will address the potential risks and uncertainties involved in achieving its future goals, an essential aspect for investors and stakeholders keen on understanding the landscape of healthcare innovation.

In addition to its conference participation, Quanterix continues to emphasize its role in enhancing research across diverse medical domains. Through its cutting-edge technology and robust laboratory capabilities, the company is well-positioned to support ongoing studies and facilitate breakthroughs in understanding complex diseases. For more information on Quanterix's innovative technologies and upcoming updates, interested parties are encouraged to visit the company's website or engage with its social media platforms.